September 28, 2016

PET agent, flurpiridaz F 18, shows promise over SPECT for cardiac imaging

Researchers have pitted PET and SPECT against each other yet again, and PET was crowned the victor. More specifically, flurpiridaz F 18, Lantheus’ investigational PET agent for myocardial perfusion imaging (MPI), was found superior to SPECT for evaluating patients with coronary artery disease (CAD) during exercise stress testing. {read more here}